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ABSTRACT
Background. Recent studies have reported improvement of
outcomes (progression-free survival, overall survival, and
prolongation of androgen deprivation treatment-free sur-
vival) with stereotactic body radiotherapy (SBRT) in non-
small cell lung cancer and prostate cancer. The aim of this
retrospective, multicenter study (MITO RT-01) was to define
activity and safety of SBRT in a very large, real-world data
set of patients with metastatic, persistent, and recurrent
ovarian cancer (MPR-OC).
Materials and Methods. The endpoints of the study were the
rate of complete response (CR) to SBRT and the 24-month actu-
arial local control (LC) rate on “per-lesion” basis. The secondary
endpoints were acute and late toxicities and the 24-month
actuarial late toxicity-free survival. Objective response rate
(ORR) included CR and partial response (PR). Clinical benefit
(CB) included ORR and stable disease (SD). Toxicity was evalu-
ated by the Radiation Therapy Oncology Group (RTOG) and the
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(EORTC) and Common Terminology Criteria for Adverse Events
(CTCAE) scales, according to center policy. Logistic and Cox
regression were used for the uni- and multivariate analysis of
factors predicting clinical CR and actuarial outcomes.
Results. CR, PR, and SD were observed in 291 (65.2%),
106 (23.8%), and 33 (7.4%) lesions, giving a rate of CB of
96.4%. Patient aged ≤60 years, planning target volume (PTV)
≤18 cm3, lymph node disease, and biologically effective dose
α/β10 > 70 Gy were associated with higher chance of CR
in the multivariate analysis. With a median follow-up of
22 months (range, 3–120), the 24-month actuarial LC rate
was 81.9%. Achievement of CR and total dose >25 Gy were
associated with better LC rate in the multivariate analysis.
Mild toxicity was experienced in 54 (20.7%) patients; of
63 side effects, 48 were grade 1, and 15 were grade 2. The
24-month late toxicity-free survival rate was 95.1%.
Conclusions. This study confirms the activity and safety
of SBRT in patients with MPR-OC and identifies clinical
and treatment parameters able to predict CR and LC rate.
The Oncologist 2020;25:e311–e320
Implications for Practice: This study aimed to define activity and safety of stereotactic body radiotherapy (SBRT) in a very
large, real life data set of patients with metastatic, persistent, recurrent ovarian cancer (MPR-OC). Patient age <60 years,
PTV <18 cm3, lymph node disease, and biologically effective dose α/β10 >70 Gy were associated with higher chance of com-
plete response (CR). Achievement of CR and total dose >25 Gy were associated with better local control (LC) rate. Mild tox-
icity was experienced in 20.7% of patients. In conclusion, this study confirms the activity and safety of SBRT in MPR-OC
patients and identifies clinical and treatment parameters able to predict CR and LC rate.
INTRODUCTION
Despite the advances in cytoreductive efforts and the incor-
poration of bevacizumab to front-line chemotherapy (CT) in
advanced ovarian cancer (OC), recurrence is a common event,
with >70% of women experiencing relapse within 2 years from
diagnosis [1]. The traditional management of patients with
recurrent ovarian cancer is represented by systemic CT chosen
on the basis of platinum sensitivity [2], even though additional
parameters have been acknowledged to contribute to the
decision-making process (e.g., histotype, status of BRCA genes
or homologous recombination deficiency, pattern of relapse).
Moreover, the introduction of Poly(ADP-Ribose)-Polymerase
inhibitors in second-line and, very recently, in first-line treat-
ment for patients with BRCA mutated OC would modify the
management of disease relapse [3–5].
In this rapidly changing scenario, the role of radiother-
apy (RT), considered up to some years ago as relegated to
the palliative setting, has been revalued. Indeed, we have
seen over time a gradual but progressive shift toward the
concept of RT as an active and definitive treatment that can
be integrated into a multidisciplinary strategy including sur-
gery, conventional CT, and the novel options derived from
target-based medicine [6–8].
In the context of high conformal and modulated tech-
niques characterized by increased dose distribution conformity,
reduced normal tissue toxicity, and potential dose escalation,
stereotactic body radiotherapy (SBRT), also known as stereotac-
tic ablative radiotherapy (SABR), represents the cutting edge of
modern RT [9–14]. SBRT delivers high radiation doses to small
volumes in few fractions (usually 3–5 fractions) and can be
employed for curative-intent treatment strategies in low-burden
primary or metastatic cancer (oligometastatic state) [15]. SBRT
is one of the options of so-called metastases-directed ther-
apy (MDT) used in numerous solid tumors; it provides a high
local control (LC) and is usually well tolerated in the majority of
patients, even though the randomized phase II SABR-COMET
trial reported 4.5% deaths due to toxicity in spite of strict dose
constraints and a requirement for peer review of RT treatment
plans [15]. In the re-irradiation setting, toxicity risks seem to be
acceptable, although appreciable risks of severe (19%–28%),
and potentially fatal (1%–10%), toxicity have been reported,
thus highlighting a careful assessment of the toxicity-benefit
ratio [16, 17].
In addition, SBRT could be integrated within the conven-
tional CT regimens, even though the documentation of grade ≥3
toxicity rate (around 9%) and one toxic death (3%) suggests a
cautious analysis of risk factors including a dose-volume histo-
gram analysis [18]. Moreover, SBRT has been demonstrated a
useful strategy for a potential delay of further systemic therapy,
frequently less effective, especially in the oligoprogression situ-
ation, as reported in other settings such as lung and prostate
cancer [19, 20].
Besides that, SBRT has been shown to be active in chemo-
resistant disease, and potentially able to mount immune re-
sponse through the release of tumor neoantigens after cell
killing, the latter allowing the synergism of SBRT with immu-
notherapeutic approaches [7, 21].
On the basis of this background and the increased confi-
dence with this technique, SBRT has been adopted more and
more frequently [10–12]; in fact, very recently, three prospec-
tive randomized studies have reported improvement of sev-
eral outcomes (progression-free survival, overall survival, and
prolongation of androgen deprivation treatment-free survival)
with SBRT in non-small cell lung cancer and prostate [22–24].
In addition, SBRT has been attempted even in unexpected
settings, such as OC, which has been considered for years as
not susceptible to benefit of a local treatment because of com-
mon documentation of diffuse abdominal disease [25–28].
There are only a few studies focusing on the role of SBRT
in patients with metastatic, persistent, recurrent (MPR)-OC
[26–28]; in addition, the relatively small size of some series
and adoption of several SBRT schedules did not allow defini-
tion of the optimal total dose, dose per fraction, and referral
dose point, as for other solid tumors [29–31].
Indeed, the identification of clinical and/or treatment
variables able to accurately predict the chance of complete
response to SBRT and the achievement of a long-term LC is
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urgently needed to optimize the efficacy-toxicity ratio and
provide indications for building specific guidelines.
The aim of this retrospective, multicenter study was to
define activity and safety of SBRT in very large, real-world
data set of patients with MPR-OC. Clinical and/or SBRT param-
eters have been analyzed to identify potential predictors of
clinical outcome.
SUBJECTS, MATERIALS, AND METHODS
Study Design and Endpoints
This is a multicenter, retrospective study (MITO RT-01) aimed
at assessing the efficacy and safety of patients with SBRT in
MPR-OC treated in Italian Radiotherapy Institutions. The study
was initiated and carried out within the Multicenter Italian Tri-
als in Ovarian cancer (MITO) group, in collaboration with the
Gynecological group of Italian Association of Radiation Oncol-
ogy (AIRO Gyn) and the Mario Negri Gynecologic Oncology
Group (MAnGO).
Patients already signed the informed consent for treat-
ment and use of their clinical data for research or educa-
tional purposes. The coprimary endpoints of the study were
the rate of clinical complete response of disease to SBRT
and as the 24-month actuarial LC (progression of disease
inside SBRT field) rate on “per-lesion” basis. The secondary
endpoints were rate and severity of acute and late toxicities
as well as the 24-month actuarial late toxicity-free survival.
Inclusion criteria were age >18 years, oligo-recurrent, per-
sistent, progressive patients with histological documentation
of OC at primary diagnosis, up to five synchronous lesions,
any site of disease, salvage surgery or other local therapies
not feasible, relative contraindication to further systemic ther-
apy because of serious comorbidities, previous severe toxicity,
unavailability of potentially active CT, and patient refusal.
Patients with an uncertain diagnosis of ovarian carcinoma
or with more than five synchronous lesions were excluded.
Oligo-recurrent, progressive patients were defined as
patients with five or less new or enlarging metastases in an
otherwise well-controlled disease status. Oligo-persistent dis-
ease was defined as five or less persistent lesions after sys-
temic therapy.
Procedures
A specific data set for standardized data collection was devel-
oped by the Principal Investigators (G.M. and G.F.). Participating
Table 1. Patient characteristics
Characteristics n (%)
All 261
















Diabetes mellitus 24 (14.2)
Thyroid disease 20 (11.8)
Autoimmune diseasesb 20 (11.8)
Any previous malignancies 17 (10.0)
Liver disease 10 (5.9)
Heart disease 6 (3.5)
Peripheral vascular disease 5 (2.9)
Osteopathy 4 (2.4)
Chronic pulmonary disease 3 (1.8)
Lymphoproliferative disease 2 (1.2)
Cerebrovascular disease 2 (1.2)
Dyslipidemia 1 (0.6)




High grade serous cell 186 (71.3)
Endometrioid 36 (13.8)
Clear cell 11 (4.2)
Undifferentiated 6 (2.3)
Mixed mullerian; carcinosarcoma 6 (2.3)
Other 16 (6.1)














Median no. of lines of previous
chemotherapy (range)
2 (1–11)





aCalculated on the number of comorbidities (n = 169).
bPemphigus, Crohn’s disease, secondary sarcoidosis, rheumatoid
arthritis, ophthalmopathy, connective tissue disease, polyneuropathy.
cCalculated on cases with available data.
Abbreviations: n.a., not applicable; SBRT, stereotactic body radiotherapy.
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centers were required to fill data sets including age, number
and type of comorbidities, histotype, number of previous sur-
geries, previous medical treatments, and previous in site radio-
therapy. Technical and dosimetric details of SBRT and data
about response of disease, acute and late toxicities, follow-up,
and outcome measures were also collected. The data of some
patients included in the previous study of Lazzari et al. [28] were
updated and incorporated to the current series.
Best radiologic response to SBRT was evaluated by com-
puted tomography scan or positron emission tomography
scan and classified according to the RECIST (version 1.1) or
PERCIST criteria.
Objective response rate (ORR) included complete response
(CR) and partial response (PR). Clinical benefit (CB) included
ORR and stable disease (SD).
Actuarial LC was defined as the time interval between
the date of SBRT and the date of inside SBRT field relapse
and/or progression of disease or the last follow-up visit.
Actuarial progression-free survival (PFS) was defined on
“per-patient” basis as the time interval between the date of
SBRT and the date of out of field progression or the last
follow-up visit; OS was defined as the time interval between
the date of SBRT and the date of death of disease or the
last follow-up visit.
Toxicity was evaluated by RTOG/EORTC and CTCAE scales,
according to center policy.
Analysis of Data and Statistical Methods
Data were retrieved from the historical database of Radia-
tion Oncologists who joined the study; data were centrally
collected at the Radiotherapy Unit of Fondazione “Giovanni
Paolo II,” Università Cattolica del S. Cuore, Campobasso, Italy,
and entered into an electronic database. The data processing
was carried out by G.M. and G.F., and advanced statistical
modeling was carried out by G.C.
Patient characteristics were represented as frequencies
and percentages for categorical variables and as medians
and ranges for continuous variables.
The differences between subgroups were tested using the
Pearson χ2 test. Statistical significance was defined as p value
< .05. Univariate and multivariate analysis of factors predicting
clinical CR on a per-lesion basis was carried out by logistic
regression. The results of the logistic regression model are
expressed as odds ratios with 95% confidence intervals.
The Kaplan-Meier method was used to analyze actuarial
outcomes; differences between subgroups were evaluated by
log-rank tests and the univariate and multivariate Cox regres-
sion analysis. Statistical analysis was performed using Stata
15.1 statistical software (StataCorp LLC; College Station, TX).
RESULTS
Fifteen radiation oncology institutions and departments
participated to the study; after evaluation of inclusion and
exclusion criteria, 261 patients with MPR-OC, carrying a
total of 449 lesions treated by SBRT between May 2005 and
November 2018, were selected for the enrollment. Data
were considered suitable for the analysis after obtaining
adequate response to specific queries.
As shown in Table 1, median age was 60 years (range,
28–85), and the vast majority of patients (83.8%) presented
Eastern Cooperative Oncology Group performance status
0–1. One hundred and seventeen patients (41.0%) had
comorbidities, mainly represented by hypertension, diabe-
tes mellitus, thyroid disorders, and autoimmune disease.
The most frequent tumor histotype was high-grade serous
(71.3%), followed by endometrioid (13.8%) and clear cell
disease (4.2%). As far as the previous treatment(s) before
SBRT are concerned, the vast majority of patients under-
went at least one cytoreductive surgery (n = 253); previous
Table 2. Features of lesions and details of SBRT (n = 449)
n (%)
Type of lesion(s)









1 lesion 146 (55.9)a
2 lesions 70 (26.8)
3 lesions 28 (10.7)
4 lesions 9 (3.4)
5 lesions 6 (2.3)
6–7 lesions 2 (0.8)b
Equipment
Linear accelerator (LINAC) 401 (89.3)
CyberKnife 34 (7.6)
Tomotherapy 11 (2.4)
Gamma Knife 3 (0.7)
Median GTV (range), cm3 4.5 (0.04–68.4)
Median PTV (range), cm3 17.9 (0.04–136.4)
Median total dose (range), Gy 25 (5–75)
Median no. of fractions (range) 4 (1–13)
Median dose/fraction, (range), Gy 8 (3–30)









Specific isodose 235 (52.3)
Isocenter 159 (35.4)
Target mean 55 (12.3)
aCalculated on the number of patients (n = 261).
bMetachronous lesions.
Abbreviations: BED, biological effective dose; GTV, gross tumor vol-
ume; PTV, planning target volume; SRS, single fraction radiother-
apy; SBRT, stereotactic body radiotherapy.
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CT was administered in 256 patients (median number of
lines, 2; range, 1–11), whereas only 9 patients (3.4%) had
been treated by previous in site RT.
SBRT Treatment on Per-Lesion Basis
Table 2 shows characteristics of lesions (n = 449) and detailed
treatment: lymph node lesions accounted for 65.0% of this
series, followed by parenchymal ones (35.0%), and themost fre-
quent anatomical district was the abdomen (55.2%), followed
by pelvis (18.5%) and thorax (14.7%).
One hundred and forty-six patients presented only one
lesion (55.9%) and received a single SBRT course, whereas
concurrent or sequential SBRT treatments were carried out
in 115 patients bearing more than one lesion.
SBRT was delivered using different machines, the linear
accelerator (LINAC) being the most frequently used (89.3%);
volumetric arc radiotherapy was the most frequently reported
technique (individual data not shown).
The median gross tumor volume was 4.5 cm3 (range,
0.04–68.4), whereas the median planning target volume (PTV)
was 17.9 cm3 (range, 0.04–136.4).
Overall, the median total dose prescription was 25 Gy
(range, 5–75), given in four fractions (range, 1–13), with a
median dose per fraction of 8 Gy (range, 3–30). because of the
variety of schedules in terms of dose and fractionation schemes
for each treatment site (Fig. 1), the biologically effective dose
(BED) was calculated using the following equation, considering
10 as the α/β ratio per OC:




The median BEDα/β10 was 50.7 Gy (range, 7.5–262.5) in
the whole series.
Three-hundred and ninety-six lesions (88.2%) were treated
by SBRT (multiple fractions), and 53 (11.8%) lesions were
treated by single fraction radiotherapy (SRS). Treatment frac-
tionations depended on the tumor location and indication;
overall, the number of lesions treated with more than five
fractions accounted for only 10.2%.
The median dose delivered by SBRT was 27 Gy (range,
18–75), with a median BEDα/β10 of 48 Gy (range, 28–262.5;
individual data not shown). The most frequent schedules
for SBRT were 8 Gy × 3 fractions, 5 Gy × 5 fractions, and
9 Gy × 3 fractions (Fig. 1A).
The median dose delivered by SRS was 24 Gy (range, 5–30);
in terms of BEDα/β10, the median BEDα/β10 was 81.6 Gy
(range, 7.5–120; individual data not shown). The most fre-
quently adopted schedule for SRS was 24 Gy × 1 fraction, as
reported in Figure 1B.
Lymph node lesions (n = 292) presented a median vol-
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Figure 1. Summary of different radiotherapy schedules according to stereotactic body radiotherapy (A) and single fraction
radiotherapy (B).
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shown), and received a median total dose of 25 Gy (range,
5–63); median number of fractions was three (range, 1–13).
Conversely, parenchyma lesions (n = 157) had a median vol-
ume of 19.4 cm3 (range, 0.03–135.8) and received the
median total dose of 27 Gy (range, 10–75); median number
of fractions was 3 (range, 1–6; individual data not shown).
Total dose was prescribed to a specific isodose (52.3%), to
isocenter (35.4%), or to the target mean (12.3%).
Efficacy
CR, PR, SD, and progressive disease (PD) were observed in
291 (65.2%), 106 (23.8%), 33 (7.4%), and 16 lesions (3.6%),
Table 3. Univariate and multivariate logistic regression of variables predicting complete response to SBRT on “per-lesion” basis
Variable n Complete response, n (%)
Univariate Multivariate
Odds ratio (95% CI) p valuea Odds ratio (95% CI) p valuea
All lesions 446b 291 (65.2)
Age, yr .048 .027
>60 213 129 (60.6) 1 1
≤60 233 162 (69.5) 1.486 (1.004–2.198) 1.616 (1.056–2.472)
Histotype .538
Serous 320 206 (64.4) 1
Others 126 85 (67.5) 1.147 (0.741–1.777)
Type of lesions <.001 <.001
Parenchyma 155 76 (49.0) 1 1
Lymph nodes 291 215 (73.9) 2.940 (1.953–4.428) 2.937 (1.888–4.569)
Total dose, Gy .928
≤25 226 147 (65.0) 1
>25 220 144 (65.4) 1.018 (0.689–1.504)
No. of fractions .868
≤4 271 176 (64.9) 1
>4 175 115 (65.7) 1.034 (0.694–1.543)
Dose/fraction, Gy .286
≤8 172 107 (62.2) 1
>8 274 184 (67.1) 1.242 (0.834–1.849)
BEDα/β10, Gy .531 .006
≤70 314 202 (64.3) 1 1
>70 132 89 (67.4) 1.147 (0.746–1.766) 1.979 (1.214–3.227)
PTV, cm3 .006 .005
>18 187 106 (56.7) 1 1
≤18 232c 162 (69.8) 1.768 (1.182–2.646) 1.857 (1.207–2.857)
Boldface = statistically significant results.
aCalculated with logistic regression.
bData relative to complete response unavailable for three lesions.
c27 missing.
Abbreviations: BED, biological effective dose; PTV, planning target volume.
Table 4. Prediction of rate of complete response to SBRT on “per-lesion” basis according to the variables included in the
model
Variables
Complete response to SBRT, % (95% confidence interval)
Age ≤60 yr Age >60 yr
PTV ≤18 cm3 PTV >18 cm3 PTV ≤18 cm3 PTV >18 cm3
Lymph node lesions
BEDα/β 10 ≤70 Gy 78.7 (72.0–85.5) 66.6 (56.8–76.4) 69.6 (61.3–77.9) 55.2 (44.3–66.2)
BEDα/β 10 >70 Gy 88.0 (81.5–94.5) 79.8 (70.7–88.9) 81.9 (73.7–90.1) 71.0 (60.6–81.3)
Parenchyma lesions
BEDα/β 10 ≤70 Gy 55.8 (44.5–67.0) 40.4 (28.7–52.2) 43.8 (31.6–56.1) 29.6 (18.4–40.8)
BEDα/β 10 >70 Gy 71.4 (59.9–82.9) 57.3 (45.1–69.6) 60.7 (47.9–73.5) 45.4 (33.4–57.4)
Abbreviations: BED, biological effective dose; PTV, planning target volume; SBRT, stereotactic body radiotherapy.
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respectively. ORR was 89%, whereas the overall CB was
96.4%.
As shown in Table 3, univariate analysis of variables
predicting CR per lesion showed that patient age ≤ 60 years,
PTV ≤18 cm3, and lymph node disease were significantly
associated with a higher probability of achieving CR. Even
though the variable BEDα/β10 did not show any association
with CR, it was considered suitable for being introduced in
the multivariate model on the basis of its role as measure of
treatment: therefore, before running the multivariate analysis,
we first verified the distribution of lymph node and parenchyma
lesions according to BEDα/β10 and demonstrated that lymph
node lesions were less frequently treated with BEDα/β10 > 70 Gy
compared with parenchyma lesions (22.2% vs. 42.6%, respec-
tively; p value < .001; individual data not shown). In this context,
we hypothesized that this latter finding could represent a con-
founding factor potentially masking the role of BEDα/β10 in
terms of achievement of CR. For this reason, we decided to
include also the variable BEDα/β10 in the multivariate analysis
together with the three above-cited parameters (Table 3). All of
them were shown to play a statistically significant independent
role in predicting clinical CR.
An easier tool providing the predicted rate of CR on per-
lesion basis according to different combinations of the vari-
ables included in the final multivariate model was enclosed in
Table 4; for instance, lymph node lesions with PTV ≤18 cm3,
treated with BEDα/β10 > 70 Gy in patients aged ≤60 years,
would have the highest chance of CR (88.0%; CI, 81.5–94.5). In
contrast, parenchymal lesions with PTV >18 cm3 treated with
BEDα/β10 ≤ 70 Gy in patients older than 60 would expect the
lowest percentage of CR (29.6%; 95% CI, 18.4–40.8).
Clinical Outcome
As of February 2019, median follow-up was 22 months
(range, 3–120): 64 patients (24.6%) were alive with no evi-
dence of disease; 111 patients (42.6%) were alive with dis-
ease in the SBRT site (n = 5), outside of field (n = 67), or
both (n = 39); and 86 patients (32.8%) had died of disease.
Table 5. Univariate and multivariate Cox regression analysis of variables predicting local control (LC) on “per lesion” basis
Variable n
Univariate Multivariate
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Total 446a
Age, yr .048 .156
≤60 233 1 1
>60 213 0.578 (0.336–0.994) 0.666 (0.381–1.167)
Histotype .491
Serous 320 1
Others 126 0.814 (0.455–1.459)
Type of lesions .651
Lymph nodes 291 1
Others 155 0.88 (0.507–1.528)
Total dose, Gy .001 .011
≤25 226 1 1
>25 220 0.374 (0.213–0.655) 0.424 (0.219–0.820)
Fractions .554
≤4 271 1
>4 175 0.855 (0.509–1.435)
Dose/fraction, Gy .059
≤8 274 1
>8 172 0.554 (0.300–1.024)
BEDα/β 10, Gy .023 .843
≤70 314 1 1
>70 132 0.456 (0.231–0.899) 0.923 (0.420–2.030)
PTV, cm3 .606
≤18 232 1
>18 187b 0.869 (0.510–1.480)
Clinical response <.001 <.001
Not complete 155 1 1
Complete 291 0.234 (0.139–0.393) 0.228 (0.135–0.384)
Boldface = statistically significant results.
aData relative to local control unavailable for three lesions.
b27 missing.
Abbreviations: BED, biological effective dose; CI, confidence interval; PTV, planning target volume.
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We documented PD in 61 of 446 irradiated lesions
(13.7%): the 24- and 36-month actuarial LC rates were 81.9%,
and 79.9%, respectively (supplemental online Fig. 1A).
Univariate analysis of variables predicting LC rate per
lesion showed that older age, total dose >25 Gy, achieve-
ment of CR, and BEDα/β10 ≥ 70Gy were significantly associ-
ated with a higher probability of LC rate (Table 5). In the
multivariate analysis, the achievement of CR and adminis-
tration of total dose >25 Gy resulted significantly associated
with better LC rate (Table 5).
As far as the outside field actuarial recurrence rate on
per-patient basis is concerned, the 24- and 36-month actu-
arial PFS rates were 15.4% and 12.7%, respectively (supple-
mental online Fig. 1B). The 24- and 36-month actuarial OS
rates were 73.6%, and 56.3%, respectively (supplemental
online Fig. 1C).
Safety
Of 261 patients, 54 patients (20.7%) experienced mild acute
toxicity, totaling 63 side effects, of which 48 were grade
1 and 15 were grade 2 (Table 6).
In contrast, only 16 patients (6.1%) presented late toxic-
ity, accounting for 19 side effects; only 2 of them were
grade 2 (pulmonary disorders). The 24- and 36-month late
toxicity-free survival rates were 95.1%, and 92.1%, respec-
tively (individual data not shown).
DISCUSSION
To the best of our knowledge, this is the largest series
focusing on efficacy and safety of SBRT in MPR-OC, having
collected data on 449 lesions from 261 patients treated in
15 radiation oncology institutions.
As far as the primary endpoint is concerned, we docu-
mented a rate of 65.2% CR of irradiated lesions; despite the
limits inherent to the heterogeneity over time of frequency and
type of imaging for assessment of clinical response, our finding
well matches with data of some OC SBRT series [26, 27]. The
100% rate of CR reported by Trippa et al. [26] is likely to be
ascribed to the small sample size and/or the inclusion of only
lymph node disease, which is recognized as presenting a
higher response to SBRT compared with parenchymal lesions
[28, 32]. A comprehensive summary of the literature focused
on SBRT in ovarian cancer is reported in supplemental online
Table 2.
In addition, we also reported PR and SD in 23.8% and 7.4%
of lesions, respectively, thus achieving a CB in 96.4% of lesions,
which is in agreement with other experiences [26–28]. Among
clinical and treatment parameters, only age ≤ 60, PTV ≤18 cm3,
lymph node disease, and BEDα/β10 > 70 Gy emerged as inde-
pendent predictors of high chances of CR.
The independent favorable role of younger age and lower
tumor volume (PTV) in predicting CR has been already re-
ported by other studies [33, 34]. Conversely, lymph node
lesions showed a higher responsiveness compared with paren-
chymal disease, and this behavior was confirmed in all settings
originated from the combinations of variables identified by
the multivariate analysis; similar findings have been men-
tioned in the literature, but these are few [27, 28], and a com-
prehensive evaluation of this issue is lacking. In the context of
the personalized medicine, further insights on intrinsic bio-
molecular features of lymph node and parenchymal lesions
would be of interest considering that in our series this vari-
able has emerged as the most powerful independent predic-
tor of CR.
As far as the LC rate is concerned, in our series SBRT
provided a high and durable rate (24-month rate: 81.9%).
Among variables associated with longer LC, achievement of
CR acts as a major driver followed by total dose >25 Gy; rel-
ative to the latter finding, it has to be acknowledged that
total dose, which contributes predominantly to BEDα/β10
value, could be used in place of it. Indeed, also in other
solid tumors a BEDα/β10 > 70 Gy was reported to be associ-
ated to a higher rate of response [34, 35].
The dose issue, in terms of total dose or BEDα/β10, repre-
sents the only modifiable variable that can makes the differ-
ence; obviously, in the real practice (as testified by the
variety of schedules summarized in Fig. 1), this assumption
needs to adjust to heterogeneity of type, site, and size of dis-
ease, patients’ features, radiation oncologists’ experience or
attitude, and availability of equipment. It has to be acknowl-
edged that the excellent results of the present series were
obtained with rather low doses (e.g., 5 Gy × 5 fractionation is
also used outside SBRT setting); this finding could be related
Table 6. Acute and late toxicity
Acute toxicities n (%) Late toxicities n (%)
All 63 All 19
Asthenia Asthenia
G1 9 (14.2) G1
G2 G2
Pain Pain
G1 6 (9.5) G1 2 (10.5)





G1 19 (30.1) G1 2 (10.5)





G1 9 (14.3) G1 8 (42.1)
G2 3 (4.7) G2
GU disorders GU disorders
G1 1 (1.5) G1 1 (5.2)





G1 1 (1.5) G1 1 (5.2)













Abbreviations: GI, gastrointestinal; GU, genitourinary.
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to a more cautious approach to SBRT schedules at the early
phase of its development.
Therefore, efforts aimed at formulating and sharing pro-
posals for optimized dose and fractionation SBRT schedules
could be helpful in order to align the approaches and pro-
vide more homogeneous and robust results.
Despite the excellent LC, which is likely to improve palliation
of symptoms and quality of life andmay prolong chemotherapy
free interval, the rate of progression outside of the target
lesions remains high, ranging between 60 and 80% [27, 28] (cur-
rent series). In this context, the data sustaining the potential
role of SBRT in increasing tumor immunogenicity and promot-
ing systemic activity suggest potential synergism between SBRT
and immunotherapy [36] (see also www.clinicaltrials.gov).
CONCLUSIONS
The efficacy of SBRT is accompanied by a quite favorable
toxicity profile in our series, thus configuring an acceptable
cost-effectiveness ratio; in particular, only 20.6% of patients
experienced low grade acute toxicity, and the 24-month late
toxicity-free survival was 95.1%. Considering that half of
patients were > 60 years, and 46% received two or more previ-
ous lines of CT and at least one major surgery, this issue is a
further confirmation of safety of this technique also in unfit set-
ting. However, we have to acknowledge that the retrospective
physician-reported toxicity scoring could have been biased,
especially in the presence of a long-term follow-up, as reported
in our study. Moreover, the risk of underestimating the rate of
late toxicity for adverse events occurring far from the irradiated
site(s) has to be recognized. For example, in the randomized
phase II SABR-COMET trial, a fatal subdural hemorrhage was
reported following surgery required to repair a SABR-related
perforated gastric ulcer [15]. In this scenario, the criteria defin-
ing abdominal-pelvic lesions not eligible for SBRT is clinically rel-
evant; in principle, all MPR-OC lesions are eligible, but the
doses and fractionation can largely vary on the basis of lesion
size, proximity to organs at risk (especially small bowel and
large vessels), previous irradiation, bowel fixity, and perfor-
mance status. In conclusion, our large, real world study con-
firms the activity and safety of SBRT in patients with MPR-OC
and identifies clinical and treatment parameters able to predict
CR and LC rate. Optimal SBRT schedules should be defined tak-
ing into account the need to guarantee the best personalized
radiation dose.
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